Cyclerion Therapeutics, Inc. (CYCN)
NASDAQ: CYCN · Real-Time Price · USD
2.930
+0.030 (1.03%)
Jan 22, 2025, 1:25 PM EST - Market open
Cyclerion Therapeutics Employees
Cyclerion Therapeutics had 1 employees as of December 31, 2023. The number of employees decreased by 15 or -93.75% compared to the previous year.
Employees
1
Change (1Y)
-15
Growth (1Y)
-93.75%
Revenue / Employee
$194,000
Profits / Employee
-$5,281,000
Market Cap
7.42M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
CYCN News
- 5 weeks ago - Cyclerion's sGC Stimulator Portfolio Generates Revenues to Enable Company Growth - GlobeNewsWire
- 6 months ago - Regina Graul, Ph.D., Promoted to Chief Executive Officer - GlobeNewsWire
- 1 year ago - Cyclerion Appoints Regina Graul, Ph.D., as President - GlobeNewsWire
- 1 year ago - Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator - GlobeNewsWire
- 1 year ago - Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets - GlobeNewsWire
- 1 year ago - Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewsWire
- 1 year ago - Cyclerion Announces Reverse Stock Split - GlobeNewsWire
- 1 year ago - Cyclerion Announces Definitive Agreement for Zagociguat and CY3018 - GlobeNewsWire